vs
CSG SYSTEMS INTERNATIONAL INC（CSGS）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSG SYSTEMS INTERNATIONAL INCの直近四半期売上が大きい（$323.1M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.1倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 2.2%、差は14.3%）。CSG SYSTEMS INTERNATIONAL INCの前年同期比売上増加率が高い（2.0% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $55.8M）。過去8四半期でCSG SYSTEMS INTERNATIONAL INCの売上複合成長率が高い（4.6% vs 1.2%）
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
CSGS vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $323.1M | $283.4M |
| 純利益 | $7.0M | $46.7M |
| 粗利率 | 50.0% | 55.5% |
| 営業利益率 | 9.0% | 29.1% |
| 純利益率 | 2.2% | 16.5% |
| 売上前年比 | 2.0% | -2.4% |
| 純利益前年比 | -79.7% | -23.5% |
| EPS（希薄化後） | $0.24 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $323.1M | $283.4M | ||
| Q3 25 | $303.6M | $274.1M | ||
| Q2 25 | $297.1M | $249.5M | ||
| Q1 25 | $299.5M | $296.5M | ||
| Q4 24 | $316.7M | $290.3M | ||
| Q3 24 | $295.1M | $283.8M | ||
| Q2 24 | $290.3M | $267.1M | ||
| Q1 24 | $295.1M | $277.0M |
| Q4 25 | $7.0M | $46.7M | ||
| Q3 25 | $20.5M | $42.2M | ||
| Q2 25 | $12.3M | $47.5M | ||
| Q1 25 | $16.1M | $50.1M | ||
| Q4 24 | $34.5M | $61.0M | ||
| Q3 24 | $19.1M | $54.4M | ||
| Q2 24 | $13.8M | $49.1M | ||
| Q1 24 | $19.5M | $49.5M |
| Q4 25 | 50.0% | 55.5% | ||
| Q3 25 | 48.1% | 55.3% | ||
| Q2 25 | 49.5% | 56.2% | ||
| Q1 25 | 48.4% | 57.3% | ||
| Q4 24 | 51.3% | 55.5% | ||
| Q3 24 | 49.4% | 55.5% | ||
| Q2 24 | 47.3% | 54.7% | ||
| Q1 24 | 46.5% | 54.8% |
| Q4 25 | 9.0% | 29.1% | ||
| Q3 25 | 10.0% | 29.1% | ||
| Q2 25 | 10.0% | 28.8% | ||
| Q1 25 | 9.8% | 29.8% | ||
| Q4 24 | 13.4% | 31.7% | ||
| Q3 24 | 10.8% | 29.7% | ||
| Q2 24 | 8.8% | 27.0% | ||
| Q1 24 | 10.8% | 29.7% |
| Q4 25 | 2.2% | 16.5% | ||
| Q3 25 | 6.7% | 15.4% | ||
| Q2 25 | 4.1% | 19.0% | ||
| Q1 25 | 5.4% | 16.9% | ||
| Q4 24 | 10.9% | 21.0% | ||
| Q3 24 | 6.5% | 19.2% | ||
| Q2 24 | 4.8% | 18.4% | ||
| Q1 24 | 6.6% | 17.9% |
| Q4 25 | $0.24 | $0.97 | ||
| Q3 25 | $0.73 | $0.86 | ||
| Q2 25 | $0.44 | $0.95 | ||
| Q1 25 | $0.57 | $1.00 | ||
| Q4 24 | $1.20 | $1.22 | ||
| Q3 24 | $0.67 | $1.09 | ||
| Q2 24 | $0.48 | $0.98 | ||
| Q1 24 | $0.68 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.0M | $62.4M |
| 総負債低いほど良い | $539.5M | $1.0B |
| 株主資本純資産 | $283.7M | $1.8B |
| 総資産 | $1.5B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 1.90× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.0M | $62.4M | ||
| Q3 25 | $158.4M | $119.1M | ||
| Q2 25 | $145.9M | $139.5M | ||
| Q1 25 | $136.0M | $97.9M | ||
| Q4 24 | $161.8M | $50.9M | ||
| Q3 24 | $118.4M | $51.5M | ||
| Q2 24 | $110.4M | $34.3M | ||
| Q1 24 | $120.8M | $46.5M |
| Q4 25 | $539.5M | $1.0B | ||
| Q3 25 | $538.6M | $993.1M | ||
| Q2 25 | $537.8M | $992.7M | ||
| Q1 25 | $537.6M | $992.4M | ||
| Q4 24 | $538.5M | $992.0M | ||
| Q3 24 | $539.5M | $1.1B | ||
| Q2 24 | $540.5M | $1.1B | ||
| Q1 24 | $541.5M | $1.1B |
| Q4 25 | $283.7M | $1.8B | ||
| Q3 25 | $289.5M | $1.8B | ||
| Q2 25 | $290.7M | $1.9B | ||
| Q1 25 | $283.1M | $1.8B | ||
| Q4 24 | $282.6M | $1.8B | ||
| Q3 24 | $288.4M | $1.7B | ||
| Q2 24 | $273.3M | $1.7B | ||
| Q1 24 | $269.3M | $1.7B |
| Q4 25 | $1.5B | $3.5B | ||
| Q3 25 | $1.5B | $3.4B | ||
| Q2 25 | $1.4B | $3.4B | ||
| Q1 25 | $1.4B | $3.4B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.4B | $3.3B | ||
| Q2 24 | $1.4B | $3.3B | ||
| Q1 24 | $1.3B | $3.3B |
| Q4 25 | 1.90× | 0.56× | ||
| Q3 25 | 1.86× | 0.54× | ||
| Q2 25 | 1.85× | 0.54× | ||
| Q1 25 | 1.90× | 0.54× | ||
| Q4 24 | 1.91× | 0.55× | ||
| Q3 24 | 1.87× | 0.61× | ||
| Q2 24 | 1.98× | 0.65× | ||
| Q1 24 | 2.01× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.2M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $55.8M | $75.3M |
| FCFマージンFCF / 売上 | 17.3% | 26.6% |
| 設備投資強度設備投資 / 売上 | 1.1% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 8.46× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $141.4M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $59.2M | $78.3M | ||
| Q3 25 | $47.9M | $57.5M | ||
| Q2 25 | $37.3M | $79.0M | ||
| Q1 25 | $11.5M | $61.8M | ||
| Q4 24 | $82.5M | $65.1M | ||
| Q3 24 | $39.5M | $69.8M | ||
| Q2 24 | $43.1M | $54.8M | ||
| Q1 24 | $-29.4M | $66.9M |
| Q4 25 | $55.8M | $75.3M | ||
| Q3 25 | $43.9M | $55.4M | ||
| Q2 25 | $34.6M | $78.2M | ||
| Q1 25 | $7.1M | $58.4M | ||
| Q4 24 | $76.6M | $63.5M | ||
| Q3 24 | $32.0M | $67.8M | ||
| Q2 24 | $38.8M | $53.6M | ||
| Q1 24 | $-34.1M | $63.8M |
| Q4 25 | 17.3% | 26.6% | ||
| Q3 25 | 14.5% | 20.2% | ||
| Q2 25 | 11.6% | 31.3% | ||
| Q1 25 | 2.4% | 19.7% | ||
| Q4 24 | 24.2% | 21.9% | ||
| Q3 24 | 10.8% | 23.9% | ||
| Q2 24 | 13.4% | 20.1% | ||
| Q1 24 | -11.6% | 23.0% |
| Q4 25 | 1.1% | 1.1% | ||
| Q3 25 | 1.3% | 0.8% | ||
| Q2 25 | 0.9% | 0.3% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 1.9% | 0.5% | ||
| Q3 24 | 2.5% | 0.7% | ||
| Q2 24 | 1.5% | 0.4% | ||
| Q1 24 | 1.6% | 1.1% |
| Q4 25 | 8.46× | 1.68× | ||
| Q3 25 | 2.34× | 1.36× | ||
| Q2 25 | 3.04× | 1.66× | ||
| Q1 25 | 0.71× | 1.23× | ||
| Q4 24 | 2.39× | 1.07× | ||
| Q3 24 | 2.07× | 1.28× | ||
| Q2 24 | 3.12× | 1.12× | ||
| Q1 24 | -1.51× | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
